Conference Description:

Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by teams who remain steadfast in their belief that this science can transform lives. Confidence is returning, with significant investments and acquisitions signalling a renewed commitment to overcoming barriers of safety, efficacy, and scalability.

The 9th Gene Therapy Development Summit returns to Boston as the meeting point for this community. Join 100+ leading voices from the likes of Bayer, Astellas Pharmaceuticals, REGENXBIO, Ocugen, AskBio, CureDuchenne Ventures, and more to come together to share ideas, restore confidence, and chart a sustainable path forward for gene therapy.

Connect with your peers in pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs for an unrivalled learning and networking opportunity across the end-to-end of gene therapy development.

URL:
Tickets: https://go.evvnt.com/3347205-2?pid=154
Time: 8:00 AM - 6:00 PM

Prices:
Drug Developer Pricing - 3 Day Pass (Conference + Focus Day): USD 4197.00,
Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,
Academic Pricing - 3 Day Pass (Conference + Focus Day): USD 3597.00,
Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,
Service Provider Pricing - 3 Day Pass (Conference + Focus Day): USD 5097.00,
Service Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adrian Veres, Co-Founder and Chief Scientific Officer, Dyno Therapeutics, Alicia Gomez, MSW, Independent Social Work Coordinator, Independent Expert, Alison Niewiarowska, Head of Biological Products Medicine and Healthcare products, Regulatory Agency, Amber Salzman, Chief Executive Officer, Epicrispr Biotechnologies, Andrea Moore, Vice President - Analytical Development and Quality Control, Asklepios BioPharmaceutical, Inc. (AskBio), Andrew Steinsapir, Director and Gene Therapy Program Lead and Acting Chief Technology Officer, Deerfield Management and Apertura Gene Therapy, Casey Maguire, Associate Professor of Neurology, Harvard Medical School, Chrissy Burton, Senior Director - Clinical Operations, BridgeBio Pharma, Inc., Craig Malzahn, Senior Vice President, REGENXBIO, Damir Simic, Executive Director and Head of Integrative Science, Astellas Pharma, Derek Jackson, Senior Vice President - Product Development, Pacira Pharmaceuticals Inc, Devyn Smith, Chief Executive Officer, Arbo Bio, Hebe Sun, Associate Director, CDx/IVD Regulatory Affairs, Regeneron Pharmaceuticals, Jon Weber, Senior Director, Cell and Amp Gene Therapy Market Access Lead, Bayer, Jorge Santiago-Ortiz, Vice President - CMC and Regulatory Affairs, Apertura Gene Therapy, Karsten Peppel, Associate Director - Gene Therapy, CSL, Lianna Orlando, Vice President - Research and Partner, CureDuchenne, Lindsay Marjoram, Director of Research, Barth Syndrome Foundation Inc, Lorelei Stoica, Executive Director, of Non-Clinical Research, Ultragenyx Pharmaceutical Inc., Mehrnaz sheibani, Postdoctoral, UT Southwestern Medical Center, Melis McHenry, Associate Director, Regeneron Pharmaceuticals, Mitra Tavakkoli, Executive Medical Lead, BridgeBio Pharma, Inc., Pushpendra Singh, Senior Director, Head of Product Development, Ocugen, Rajeev Boregowda, Associate Director, Bioassay and Molecular Analytical Development, Genomic Medicine CMC, Sanofi, Ralf Schmid, Independent Expert, Independent Expert, Roelof Rongen, Chief Executive Officer Adolore, BioTherapeutics, Stephen Poor, Head of Translational Medicine, Apellis Pharmaceuticals, Tassos Georgiadis, Senior Vice President Discovery and Preclinical Development, MeiraGTx, Thomas Dee, CEO, Endsulin, TJ Cradick, Chief Scientific Officer, Gene Editing Frontiers, William Pu, Director of Basic and Translational Research, Department of Cardiology, Boston Children’s Hospital; Aldo R. Casteñeda Professor, Harvard Medical School and Boston Children's Hospital